Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell-based therapy for insulin-dependent diabetes mellitus

S Efrat1

  • 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

European Journal of Endocrinology
|March 20, 1998
PubMed
Summary

Transgenic mouse beta-cell lines offer a reproducible source for diabetes treatment. Gene modification enhances their function and survival for potential transplantation therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanisms of adult human β-cell in vitro dedifferentiation and redifferentiation.

Diabetes, obesity & metabolism·2016
Same author

In vitro expansion and redifferentiation of adult human islet cells.

Journal of stem cells & regenerative medicine·2014
Same author

In vitro expansion of human beta cells.

Diabetologia·2008
Same author

Correction of hyperglycemia in diabetic mice transplanted with reversibly immortalized pancreatic beta cells controlled by the tet-on regulatory system.

Cell transplantation·2001
Same author

Inducible and reversible beta-cell autoimmunity and hyperplasia in transgenic mice expressing a conditional oncogene.

Diabetes·2001
Same author

Cell therapy approaches for the treatment of diabetes.

Current opinion in investigational drugs (London, England : 2000)·2001

Area of Science:

  • Endocrinology
  • Cell Biology
  • Regenerative Medicine

Background:

  • Insulin-dependent diabetes mellitus (Type 1 diabetes) requires effective beta-cell replacement therapies.
  • Pancreatic beta-cell lines offer a scalable alternative to primary islets for transplantation.
  • Existing beta-cell lines require methods for controlled replication and enhanced survival.

Purpose of the Study:

  • To develop and optimize insulin-secreting beta-cell lines for diabetes treatment.
  • To investigate methods for regulating beta-cell line replication and function.
  • To enhance beta-cell line survival and allogeneic transplantability.

Main Methods:

  • Development of transgenic mouse beta-cell lines with high insulin production.
  • Utilizing a reversible transformation approach for controlled cell replication in vitro and in vivo.
  • Employing gene transfer with adenovirus vectors to modulate antigen presentation and cytokine resistance.

Main Results:

  • Transgenic beta-cell lines produce insulin comparable to native islets and respond to secretagogues.
  • Reversible transformation allows tight regulation of beta-cell line proliferation.
  • Adenovirus-mediated gene transfer improved mouse beta-cell survival and reduced immunogenicity, facilitating transplantation across allogeneic barriers.

Conclusions:

  • Regulated beta-cell lines are a viable source for diabetes cell therapy.
  • Genetic engineering can overcome key barriers to beta-cell transplantation.
  • These strategies hold potential for developing human beta-cell lines for clinical application.

Related Experiment Videos